telbivudine is associated with improvement of renal function in patients after liver transplantation...
TRANSCRIPT
TELBIVUDINE IS ASSOCIATED WITH IMPROVEMENT OF RENAL FUNCTION IN PATIENTS AFTER LIVER TRANSPLANTATION
1 Maria Ioannidou, 1 Evangelos Cholongitas, 2 Themistoklis Vasiliadis, 1 Ioannis Goulis, 1 Georgia
Moisidou, 1 Zoe Valari, 1 Parthenis Chalevas, 1Stergios Soulaidopoulos, 1 Theodora
Oikonomou, 1 Evangelos Akriviadis
1 4th Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Medical School of Aristotle University
2 3rd Internal Medicine Department, Aristotle University of Thessaloniki, Papageorgiou Hospital
• Nucleos(t)ide analogues [NA(s)] has evolved the therapeutic
manipulation of patients with chronic hepatitis B (CHB) improving the
outcome of HBV transplant patients after liver transplantation (LT).
• NAs have been used, either as monoprophylaxis or in combination
with hepatitis B immune globulin (HBIG) after LT.
BACKGROUND
• During long-term therapy with NAs in CHB patients, minimal rates of
GFR decline have been reported, except for telbivudine
• LT recipients may represent a group of patients, in which the role of
telbivudine needs further evaluation, because these patients are
considered at high risk for renal dysfunction due to the concomitant
use of the calcineurin inhibitors (CNIs)
BACKGROUND
OBJECTIVES
To evaluate the impact of telbivudine on renal function in liver transplant (LT) recipients
• 34 recipients were included in this prospective study
• Inclusion criteria:
a) they had no evidence of HBV recurrence, and
b) they were under stable immunosuppression regimen without
steroids during the last 12 months before baseline
MATERIALS & METHODS
• In 17 recipients (study group 1) remained on the same NA(s) as before baseline
and were followed for 12 months (1st period). At this time point (month 12), they
were switched to telbivudine monoprophylaxis for another 12 months (2nd period).
• The rest 17 (group 2) patients continued their original non-telbivudine NA(s)
prophylaxis.
• The changes GFR (ΔGFR) between baseline and after 12 months (1st period) and
between 12 months and 24 months (2nd period) were evaluated.
MATERIALS & METHODS
Tenofovir (N=13), Lamivudine (N=2) Lamivudine + Adefovir (N=2)
No-Telbivudine prophylaxis (n=34)
Baseline 12 monthsLT
2nd period1st period
Serum creatinineand GFR
Serum creatinineand GFR
Serum creatinineand GFR
24 months
HBVDNA (-)HBsAg (-)
Entecavir (N=5), Tenofovir (N=4), Lamivudine + Adefovir (N=8)
Group 2 (n=17)
Group 1 (n=17)
Telbivudine monoprophylaxis
LT: liver transplantation
Variable (unit) Group 1 patients (n=17)
Group 2 patients(n=17)
P value
Age (years) 59±6 54±14 0.9
Sex, Male n, (%) 14 (82) 14 (82) 0.8
Cormobidities after LT, n (%) Diabetes mellitus, n (%) Arterial Hypertension, n (%)
0 (0)1 (6)
6 (35)2 (12)
0.710.93
Laboratory
Creatinine (mean±SD, mg/dL) 1.2±0.2 1.1±0.3 0.09
Urea (mean±SD, mg/dL) 42±11 40±18 0.32
MDRD-based GFR (mean±SD, mL/min) 72±18 82.3±24 0.17
CKD-EPI-based GFR (mean±SD, mL/min)
70.9±15 80±22 0.15
Immunosuppression CNIs+MMF, n (%) Serum levels of cyclosporine (mean±SD, ng/mL)
12 (71)43±28
14 (82)44±16
0.420.85
Antiviral prophylaxis, n (%) Nucleoside alone Nucleotide ( ±nucleoside)
2 (12)15 (88)
5 (29)12 (71)
0.21
Table 1. Baseline characteristics of group 1 patients (n=17) with conversion to telbivudine at 12 months and group 2 patients (n=17) without telbivudine conversion. -
72
67,8
70,370,9
66,7
70,7
50
55
60
65
70
75
MDRD
CKD-EPI
Baseline 12 months 24 months
Time after baseline (months)
Mea
n va
lues
of G
FR in
gro
up 1
pati
ents
* p=0.025 p=0.017
ml/min
*
*
#
#
#
Evolution of renal function in group 1 patients as calculated by
MDRD and CKD-EPI
35
41
23,5
29,5
41
29,5
0
5
10
15
20
25
30
35
40
45
MDRD
CKD-EPI
Baseline 12 months 24 months
Time after baseline (months)
% o
f pati
ents
with
GFR
< 6
0mL/
min
in g
roup
1 p
atien
ts %
Proportion of patients with GFR < 60mL/min in group 1
patients using the MDRD and CKD-EPI formulae
60
65
70
75
80
85
72
67.8
70.3
82.3
79.2
75.8
Group 1
Group 2 (control)
Time (months) Baseline 12 mo 24 mo
GFR
(mL/
min
, MD
RD fo
rmul
a)
1st period 2nd period
Tenofovir (N=13)Lamivudine ± Adefovir (N=4) Telbivudine (N=17)
Entecavir (N=5), Tenofovir (N=4)Lamivudine + Adefovir (N=8)
-4.2mL/min
+2.5 mL/min
Evolution of renal function in group 1 and 2 patients as calculated by MDRD
CONCLUSIONS
• We showed that telbivudine administration in LT recipients for HBV cirrhosis was effective and it was associated with significant improvement in renal function,
• However, this remains to be confirmed in larger well-designed studies